Marker Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for MRKR, updated each market day.
MRKR AI Sentiment
AI sees no strong directional signal for Marker Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Marker Therapeutics, Inc. Common Stock
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Sector
Exchange
Market Cap
$24,176,034
Cap Tier
Employees
5
Headquarters
HOUSTON, TX
Listed Since
Jan. 7, 1998
MRKR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MRKR Volatility
Marker Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
